Company intelligence / Profile preview

adivo

Martinsried (Munich area), Bavaria, Germany

Ownership: Private
Employees: ~25
Development stage: Other

Overview

adivo has developed species-specific monoclonal antibody candidates for companion animals (dogs, cats), with promising preclinical and early veterinary trial results, including limited market authorization for its lead oncology program and clinical evaluation of canine solid tumor therapy begun in 2023.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodyAntibody
Industry: Veterinary

Partnerships

Zoetis (acquirer, collaboration since 2021)Bayer Animal Health (previous global collaboration agreement announced in 2019)FyoniBio GmbH (manufacturing partnership)

Beyond the preview

Go deeper on adivo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adivo.

Explore the full profile